Epidemiological Features and Predictors of Mortality in Patients with COVID-19 with and without Underlying Hypertension

Abstract

Backgrounds. Individuals with hypertension are at higher risk of COVID-19 infection and related mortality. This study was carried out to assess the epidemiological features and predictors of mortality in patients with COVID-19 with hypertension. Methods. In this retrospective study, the epidemiological characteristics of two groups of patients with COVID-19 with hypertension (1927) and without hypertension (39030) were compared. Chi-square test was applied to evaluate the differences between qualitative variables in two study groups. Logistic regression was also used to determine predictors of mortality in patients with COVID-19 and in patients with COVID-19 with hypertension. Results. The prevalence of hypertension in patients with COVID-19 was 4.7%, and 24.37% of COVID-19 related deaths occurred in these individuals. The average age of hypertension and nonhypertension patients was 61 and 37 years, respectively. Fever, cough, headache, anorexia, fatigue, and comorbid diseases, such as cardiovascular disease, chronic lung and kidney disease, diabetes, immunodeficiency disease, and thyroid disease, were significantly more frequent in people with hypertension than those without hypertension. The chances of mortality in patient with COVID-19 were 1.8 times higher in individuals with dyspnea, 1.25 in individuals with fever, 1.33 in individuals with cough, 3.6 in patients with hypertension, 2.21 in diabetics, and 2.2 in individuals with cardiovascular disease. Also, individuals with COVID-19 with hypertension that had dyspnea, immunodeficiency, and cardiovascular disease were at higher risk of mortality. Conclusion. Hypertension is a serious threat to patients with COVID-19. Therefore, in order to control these patients more precisely and reduce mortality in them, it is extremely important to develop prevention and treatment strategies.

Risk Factors Associated with Severity and Death from COVID-19 in Iran: A Systematic Review and Meta-Analysis Study

“…After deleting duplicates, we identified 2463 studies from four databases and then screened articles by title and full text according to the study's objectives. Finally, 69 studies were included in the meta-analysis (Figure 1), of which 62 studies had assessed risk factors for death from COVID 28–89 ); 13 studies determined risk factors for severity (( 41,50,53–55,65,…”

Antihypertensive Drugs Therapy in Hypertension and Covid-19 Comorbidity

“… Prevalence of hypertension in people with COVID-19 was 25.4% in Africa, 31% in China, 49% in Italy, 21% in India, 32% in Oman, and 10% in Iran (Cook, 2020).  The prevalence of hypertension in patients with COVID-19 was 4.7%, and 24.37% of COVID-19 related deaths occurred in individuals in Iran (Moftakhar et al, 2021).  Hypertension was the most prevalent reported comorbidity in COVID-19 patients in Wuhan; the reported prevalence rates ranged from 15.0% to 36.5% (Haung et al, 2020).…”